18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.Primary· 30 days after hospital discharge
Composite endpoint (CE) of venous and arterial thrombotic complications-including new, symptomatic proximal, or distal DVT of the upper or lower extremities, PE, and new thrombosis of other veins (including cerebral sinus and splanchnic veins), ischemic stroke, myocardial infarction, other arterial thromboembolism (e.g., mesenteric or acute limb ischemia), and all-cause mortality by day 30.
Group
Value
95% CI
Placebo
2.31
1.27 – 3.84
Apixaban
2.13
1.14 – 3.62
The Composite Outcome of All-cause Mortality and the EuroQoL Group 5-Dimension (EQ5D) Index Score.Secondary· 30 days after hospital discharge
Composite endpoint of mortality and EQ5D index at Day 30. All mortality events will be considered worse than any possible EQ5D response \[QOL\&M30\]. Death was designated as a score of 0. Scores range from 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility.
Group
Value
95% CI
Placebo
0.93
0.78 – 1.00
Apixaban
0.93
0.75 – 1.00
The Composite Outcome of All-cause Mortality and the EQ5D Index Score.Secondary· 90 days after hospital discharge
Composite endpoint of mortality and EQ5D index at Day 90. All mortality events will be considered worse than any possible EQ5D response. Death was designated as a score of 0. Scores range from 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility.
Group
Value
95% CI
Placebo
0.94
0.76 – 1.00
Apixaban
0.94
0.74 – 1.00
The Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.Secondary· 45 days after hospital discharge
Group
Value
95% CI
Placebo
2.80
1.64 – 4.44
Apixaban
2.46
1.38 – 4.02
The Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.Secondary· 90 days after hospital discharge
Group
Value
95% CI
Placebo
2.80
1.64 – 4.44
Apixaban
3.11
1.89 – 4.82
New, Symptomatic VTE (Inclusive of DVT, PE, or Other Venous Thrombosis) for up to 30 Days After Randomization as Measured by Hospital Records.Secondary· 30 days after randomization (which occurred at time of hospital discharge)
Group
Value
95% CI
Placebo
0.82
0.27 – 1.91
Apixaban
0.82
0.27 – 1.90
New, Symptomatic ATE (Inclusive of Ischemic Stroke, MI, or Peripheral Arterial Thromboembolism) for up to 30 Days After Randomization as Measured by Hospital Records.Secondary· 30 days after randomization (which occurred at time of hospital discharge)
Group
Value
95% CI
Placebo
0.49
0.10 – 1.44
Apixaban
0.16
0.00 – 0.91
Percentage of Participants With All-cause MortalitySecondary· 30 days following discharge from hospital
Group
Value
95% CI
Placebo
1.48
0.68 – 2.80
Apixaban
1.31
0.57 – 2.57
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to the 90 day visit.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Apixaban
Serious: 71/610 (12%)
Deaths: 12/610
Placebo
Serious: 66/607 (11%)
Deaths: 9/607
Serious adverse events (74 terms)
Reaction
System
Apixaban
Placebo
WORSENING COVID-19 PNEUMONIA
Infections and infestations
—
—
PNEUMONIA
Infections and infestations
—
—
CHEST PAIN
General disorders
—
—
WORSENING PNEUMONIA
Infections and infestations
—
—
DIABETIC KETO ACIDOSIS
Metabolism and nutrition disorders
—
—
PULMONARY EMBOLI
Respiratory, thoracic and mediastinal disorders
—
—
C. DIFFICILE COLITIS
Infections and infestations
—
—
CELLULITIS
Infections and infestations
—
—
COPD EXACERBATION
Respiratory, thoracic and mediastinal disorders
—
—
DEEP VEIN THROMBOSIS
Vascular disorders
—
—
GENERAL WEAKNESS
General disorders
—
—
PULMONARY EMBOLISM
Respiratory, thoracic and mediastinal disorders
—
—
ACUTE APPENDICITIS
Infections and infestations
—
—
ACUTE ASTHMA EXACERBATION
Respiratory, thoracic and mediastinal disorders
—
—
ACUTE DIFFUSE MYALGIAS
Musculoskeletal and connective tissue disorders
—
—
ACUTE REJECTION ON TRANSPLANTED KIDNEY
Immune system disorders
—
—
ALCOHOL DETOXIFICATION
Surgical and medical procedures
—
—
APPENDICITIS
Infections and infestations
—
—
ASTHMA EXACERBATION
Respiratory, thoracic and mediastinal disorders
—
—
ATRIAL FIBRILLATION
Cardiac disorders
—
—
ATYPICAL CHEST PAIN
General disorders
—
—
BILATERAL LOWER EXTREMITY CELLULITIS
Infections and infestations
—
—
BILATERAL PULMONARY EMBOLI
Respiratory, thoracic and mediastinal disorders
—
—
BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA
Respiratory, thoracic and mediastinal disorders
—
—
BRONCHOSPASM
Respiratory, thoracic and mediastinal disorders
—
—
Other adverse events (124 terms — click to expand)
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
· NA
· recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
· NA
· recruiting
NCT06523959 — Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
· Phase 4
· recruiting
NCT05304455 — Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
· NA
· completed
NCT04746339 — Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
· Phase 4
· terminated
Other recruiting trials for Covid19
Currently open trials in the same condition.
NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
· EARLY_PHASE1
· active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
· NA
· recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
· NA
· active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry
· recruiting
NCT04806061 — Urine Alkalinisation in COVID-19
· NA
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas L. Ortel
Last refreshed: 25 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650087.